Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Shanghai Henlius Biotech Inc.
Headquarters: Shanghai, China
Website: http://www.henlius.com/en/i...
Year Founded: 2009
Status: Public
Industry Sector: HealthTechnology
CEO: Jun Zhu, EMBA
Number Of Employees: 3,637
Enterprise Value: $1,409,484,783
PE Ratio: 22.45
Exchange/Ticker 1: HKEX:2696
Exchange/Ticker 2: N/A
Latest Market Cap: $2,163,939,869
BioCentury | Jul 1, 2024
Deals
Deals Report: Eisai regains ADC’s rights from BMS; Lilly’s latest radiopharma play
Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira
BioCentury | Oct 27, 2023
Politics, Policy & Law
Oct. 27 Quick Takes: AbbVie pegs IRA cost at $2.1 billion
Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more
BioCentury | Sep 8, 2022
Product Development
Sept. 8 Quick Takes: Detailed APOLLO-B data lift Alnylam shares
Plus Autobahn heads for treatment-resistant depression with $32M round and updates on Amylyx, Reata, Integral Molecular and more
BioCentury | Apr 23, 2022
Product Development
How biotechs are coping with lockdown in Shanghai
Staff at whitelisted companies living at their workplaces
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Aug 1, 2020
Product Development
July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck
BioCentury | May 8, 2020
Product Development
Japanese approval for Gilead’s remdesivir
Plus Plasma Alliance partners with NIAID; and three Chinese biotechs join to make antibody therapy
BioCentury | Dec 13, 2019
Financial News
First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum
BioCentury | Oct 28, 2019
Financial News
After Hong Kong IPO lull, local demand lifts Ascentage offering
Items per page:
1 - 10 of 24